ATE283050T1 - Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie - Google Patents

Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie

Info

Publication number
ATE283050T1
ATE283050T1 AT98941662T AT98941662T ATE283050T1 AT E283050 T1 ATE283050 T1 AT E283050T1 AT 98941662 T AT98941662 T AT 98941662T AT 98941662 T AT98941662 T AT 98941662T AT E283050 T1 ATE283050 T1 AT E283050T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
delayed release
release compositions
component
Prior art date
Application number
AT98941662T
Other languages
English (en)
Inventor
Michael Myers
Pradeepkumar P Sanghvi
Original Assignee
Biovail Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11041609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE283050(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Internat Ltd filed Critical Biovail Internat Ltd
Application granted granted Critical
Publication of ATE283050T1 publication Critical patent/ATE283050T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT98941662T 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie ATE283050T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19970731A IE970731A1 (en) 1997-10-07 1997-10-07 Product and method for the treatment of hyperlipidemia
PCT/IB1998/001489 WO1999017774A1 (en) 1997-10-07 1998-07-20 Product and method for the treatment of hyperlipidemia

Publications (1)

Publication Number Publication Date
ATE283050T1 true ATE283050T1 (de) 2004-12-15

Family

ID=11041609

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98941662T ATE283050T1 (de) 1997-10-07 1998-07-20 Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie

Country Status (9)

Country Link
US (1) US6090830A (de)
EP (1) EP0969838B2 (de)
AT (1) ATE283050T1 (de)
AU (1) AU8995598A (de)
CA (1) CA2273298C (de)
DE (1) DE69827777T9 (de)
ES (1) ES2235357T5 (de)
IE (1) IE970731A1 (de)
WO (1) WO1999017774A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
EP1117384A1 (de) * 1998-10-01 2001-07-25 Elan Pharma International Limited Nanopartikelformulierungen mit kontrollierter wirkstofffreisetzung
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US7503493B2 (en) * 1999-10-25 2009-03-17 Silverbrook Research Pty Ltd Method and system for digitizing freehand graphics with user-selected properties
WO2001032162A1 (en) * 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd Liver selective therapy
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ES2274013T3 (es) 2001-01-26 2007-05-16 Schering Corporation Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US20040067918A1 (en) * 2002-03-18 2004-04-08 Keller Bradley T. Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (de) 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP1825847A3 (de) * 2006-02-24 2008-01-23 Teva Pharmaceutical Industries Ltd Pharmazeutische Zusammensetzungen mit Fluvastatin-Natrium
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
US20100305074A1 (en) * 2007-04-04 2010-12-02 Hight H Thomas Niacin-based pharmaceutical compositions
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
US20110123609A1 (en) * 2008-07-19 2011-05-26 Sunil Shantwan Borude Multiple unit dosage form of niacin
CN101836987B (zh) * 2009-03-19 2013-03-27 西安万隆制药股份有限公司 一种复方烟酸缓释片
US20190111064A1 (en) * 2017-10-18 2019-04-18 Interstice Therapeutics, LLC Statin + vitamin d combination drug and method of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1255805A (en) * 1967-12-16 1971-12-01 Albert Ag Chem Werke Improvements in delayed release pharmaceutical preparations and stabilisation of vitamins
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5458823A (en) * 1994-10-28 1995-10-17 Fuisz Technologies Ltd. Method and apparatus for spinning feedstock material
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
DK1017390T3 (da) † 1997-07-31 2007-06-11 Kos Life Sciences Inc Coated tablet, der omfatter nikotinsyre eller en forbindelse, der metaboliseres til nikotinsyre, i en form med langvarig frigivelse og en HMG-CoA-reduktaseinhibitor i en form med öjeblikkelig frigivelse

Also Published As

Publication number Publication date
CA2273298C (en) 2008-04-08
DE69827777T9 (de) 2010-11-11
EP0969838B1 (de) 2004-11-24
DE69827777T2 (de) 2005-12-22
IE970731A1 (en) 2000-10-04
DE69827777T3 (de) 2010-07-29
DE69827777D1 (de) 2004-12-30
ES2235357T3 (es) 2005-07-01
WO1999017774A1 (en) 1999-04-15
US6090830A (en) 2000-07-18
EP0969838A1 (de) 2000-01-12
CA2273298A1 (en) 1999-04-15
EP0969838B2 (de) 2010-01-13
ES2235357T5 (es) 2010-03-30
AU8995598A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
ATE283050T1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung der hyperlipidämie
SE9704870D0 (sv) New pharmaceutical formulation I
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DE69907977D1 (de) Pyrrolobenzodiazepine
EP0529854A3 (en) Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as hmg-coa reductase inhibitors
FI981437L (fi) PDE III, PDE IV ja TNF inhibiittoreina käyttökelpoisia imidejä
IL104041A0 (en) Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor compound
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
TW200517145A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MX9308199A (es) Inhibidores de enzima.
PL345030A1 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
NO942994D0 (no) Aminoacetylmercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
DE69720778D1 (de) ARZNEIMITTEL ZUR VERZÖGERTEN FREISETZUNG DES HMG-CoA REDUKTASE INHIBITORS FLUVASTATIN
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
IS4951A (is) Lyfjablanda sem er andsegavirk og vinnur gegn myndun fituskellu í slagæð sem inniheldur þíenópýridínafleiðu og HMG-CoA redúktasahemil
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL
CU20000140A7 (es) Combinaciones de estatina-carboxialquileter
NO996519D0 (no) Doseringsformer av sertralin med forsinket frigjoering
ATE451103T1 (de) Zusammensetzung zur behandlung von atherosklerose,die candesartan und rosuvastatin enthält
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
BG100248A (bg) Инхибитори на скваленсинтетаза
DE10085183T1 (de) Zubereitung eines HMG-COA Reduktase-Inhibitors mit verlängerter Freisetzungsdauer
BG104119A (en) A new composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties